技术评估：WX - G250，威利克斯/路德维希癌症研究所。
Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
作者信息
Kennett Roger H
机构信息
Department of Biology, Wheaton College, Wheaton, IL 60187, USA.
出版信息
Curr Opin Mol Ther. 2003 Feb;5(1):70-5.
PMID:12669474
Abstract
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
摘要
Wilex公司与路德维希癌症研究所合作，正在研发WX-G250，这是一种源自小鼠单克隆抗体G250可变区的κ轻链嵌合抗体，用于潜在治疗胆管癌和肾细胞癌（RCC）。该抗体目前正在进行针对肾细胞癌的II期临床试验以及针对胆管癌的临床前开发。
Zotero 插件